Sanofi today announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), marked by a signed Letter of Intent (LOI) for Sarclisa® (isatuximab) intravenous (IV) in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the first-line treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 3% year on year to $68.3 million. The company’s full-year revenue guidance of $400 million at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.19 per share was 54.8% above analysts’ consensus estimates.
Janet Stockley-Pollard's children are among those living with the effects of sodium valproate use.
Detailed price information for Novavax Inc (NVAX-Q) from The Globe and Mail including charting and trades.
Its partner is a highly rated biotech stock that was forming a consolidation ahead of the news.
Investing.com -- Nurix Therapeutics Inc. (NASDAQ:NRIX) shares fell 34% in after-hours trading Tuesday following Sanofi’s decision to discontinue development of SAR448272, an oral STAT6 degrader.
Motley Fool Press Release.
Sanofi SA (SNY) raised its 2026 outlook to low-teens sales growth and mid-teens business EPS growth after Q3 sales rose 14.3% to EUR14.4 billion, led by Dupixent and a new launch portfolio up 19.2%.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Regeneron stock popped Thursday after its Sanofi-partnered allergic conditions drug, Dupixent, easily beat sales calls.
Regeneron Pharmaceuticals (REGN) stock rises as the company posts higher-than-expected Q3 2026 results thanks to its Sanofi (SNY) collaboration. Read more here.
The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.
By Bhanvi Satija LONDON, Oct 30 (Reuters) - French drugmaker Sanofi said on Friday that dealmaking will be an important part of replenishing the company's drug pipeline under new CEO Belen Garijo,
Sanofi lifts 2026 guidance after a strong Q3 earnings beat, fueled by Dupixent and new drug launches.
This is the newest page. Registered accounts read further back.